Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

(2014) Christian Confavreux et al.   LANCET NEUROLOGY

Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies

(2014) Dean M. Wingerchuk et al.   MAYO CLINIC PROCEEDINGS

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform

(2014) Vilija G. Jokubaitis et al.   PLoS One

Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis

(2013) Omar Khan et al.   ANNALS OF NEUROLOGY

Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial

(2013) Claudio Gobbi et al.   BMC Neurology

Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study

(2013) Neetu Agashivala et al.   BMC Neurology

BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety

(2013) Robert J. Fox et al.   CURRENT MEDICAL RESEARCH AND OPINION

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT

(2013) G. Edan et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial

(2013) Patrick Vermersch et al.   Multiple Sclerosis Journal

Immune Therapy of Multiple Sclerosis - Future Strategies

(2012) Sven G. Meuth et al.   CURRENT PHARMACEUTICAL DESIGN

Survival in MS

(2012) D.S. Goodin et al.   NEUROLOGY

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study

(2012) Douglas S Goodin et al.   BMJ Open

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis

(2012) Paul I. Creeke et al.   Therapeutic Advances in Neurological Disorders

Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis

(2011) Douglas S Goodin et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis — Results of the BetaPlus observational cohort study

(2011) Carlo Pozzilli et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

(2011) Douglas S Goodin et al.   Multiple Sclerosis Journal

Interferon  -1b and glatiramer acetate effects on permanent black hole evolution

(2011) M. Filippi et al.   NEUROLOGY

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

(2010) G. C. Ebers et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Cross-sectional study assessing long-term safety of interferon- -1b for relapsing-remitting MS

(2010) A. T. Reder et al.   NEUROLOGY

Improving Compliance with Interferon-β Therapy in Patients with Multiple Sclerosis

(2009) Emilio Portaccio et al.   CNS DRUGS

High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis

(2009) Hans-Peter Hartung   EXPERT OPINION ON PHARMACOTHERAPY

New acute and chronic black holes in patients with multiple sclerosis randomised to interferon beta-1b or glatiramer acetate

(2009) D Cadavid et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study

(2009) D. Cadavid et al.   NEUROLOGY

Safety and Tolerability in Relapsing-Remitting Multiple Sclerosis Patients Treated With High-Dose Subcutaneous Interferon-Beta by Rebiject Autoinjection Over a 1-Year Period

(2008) Alessandra Lugaresi et al.   CLINICAL NEUROPHARMACOLOGY

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET

Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway

(2008) N Grytten Torkildsen et al.   Multiple Sclerosis Journal